2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1710

Polypharmacy in Older Adults with Systemic Lupus Erythematosus
Abstract Number: 1711

Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
Abstract Number: 1712

Validation of Proposed EULAR/Acr SLE Classification Criteria Versus SLICC SLE Classification Criteria
Abstract Number: 1713

Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension
Abstract Number: 1714

Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Abstract Number: 1715

Safety and Efficacy of Lenabasum in an Open-Label Extension of a Phase 2 Study in Diffuse Cutaneous Systemic Sclerosis Subjects
Abstract Number: 1716

Evaluation of American College of Rheumatology Provisional Composite Response Index in Systemic Sclerosis in a Phase II Trial of Abatacept Vs. Placebo
Abstract Number: 1717

Expert Consensus on the Screening, Treatment, and Management of Patients with Systemic Sclerosis-Interstitial Lung Disease, and the Potential Role of Anti-Fibrotics in a Treatment Paradigm for Systemic Sclerosis-Interstitial Lung Disease: A Delphi Consensus Study
Abstract Number: 1718

Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
Abstract Number: 1719

High-Throughput Quantitative Histology in Systemic Sclerosis Skin Disease Using Computer Vision
Abstract Number: 1720

Higher Neutrophil Count Predicts More Severe Skin/Lung Disease and Increased Mortality in Early Systemic Sclerosis
Abstract Number: 1721

Racial Differences in SSc Disease Presentation: A Cross-Sectional European Scleroderma Trials and Research Group Study
Abstract Number: 1722

Patient-Level Factors Associated with Hospital Readmission Among Patients with Systemic Sclerosis Associated Pulmonary Hypertension
Abstract Number: 1723

Intensified B-Cell Depletion Therapy in Progressive Systemic Sclerosis Patients: 24 Months Follow-up
Abstract Number: 1724

Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].